Details of the Drug

General Information of Drug (ID: DM29XGY)

Drug Name

HMPL-004

Synonyms

Nuclear factor kappa B inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; TNF alpha ligand inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-1 beta modulator (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-6 antagonist (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Phase 3	[1]
------------------------------------------------------------------------------------

Cross-matching ID

PubChem CID: 5318517
TTD ID: D0G6DF

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inflammation pathogenesis (IP)	TTBD054	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-AMP-activated protein kinase subunit gamma-2 (PRKAG2)	OTHTAM54	AAKG2_HUMAN	Gene/Protein Processing	[3]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Gene/Protein Processing	[4]
Actin, aortic smooth muscle (ACTA2)	OTEDLG8E	ACTA_HUMAN	Gene/Protein Processing	[5]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[3]
AN1-type zinc finger protein 2A	OTTG7P8R	ZFN2A_HUMAN	Gene/Protein Processing	[3]
Antigen peptide transporter 1 (TAP1)	OTJL27PW	TAP1_HUMAN	Gene/Protein Processing	[3]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[6]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[7]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Gene/Protein Processing	[3]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01882764) A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
3	Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
4	Andrographolide inhibits the growth of human osteosarcoma cells by suppressing Wnt/-catenin, PI3K/AKT and NF-B signaling pathways. Chem Biol Interact. 2022 Sep 25;365:110068. doi: 10.1016/j.cbi.2022.110068. Epub 2022 Jul 31.
5	Natural product andrographolide alleviated APAP-induced liver fibrosis by activating Nrf2 antioxidant pathway. Toxicology. 2018 Mar 1;396-397:1-12.
6	Andrographolide sensitizes the cytotoxicity of human colorectal carcinoma cells toward cisplatin via enhancing apoptosis pathways in vitro and in vivo. Toxicol Sci. 2014 May;139(1):108-20. doi: 10.1093/toxsci/kfu032. Epub 2014 Feb 22.
7	Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Toxicol Lett. 2013 Sep 12;222(1):23-35. doi: 10.1016/j.toxlet.2013.06.241. Epub 2013 Jul 8.